Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Operating Cash Flow per Share : $-0.65 (TTM As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings Operating Cash Flow per Share?

Arcturus Therapeutics Holdings's operating cash flow per share for the three months ended in Dec. 2023 was $-0.02. Arcturus Therapeutics Holdings's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.65.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Arcturus Therapeutics Holdings was -157.60% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 31.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Arcturus Therapeutics Holdings's Operating Cash Flow per Share or its related term are showing as below:

ARCT' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -142 Med: 27.6 Max: 78.3
Current: 31.5

During the past 13 years, Arcturus Therapeutics Holdings's highest 3-Year average Operating Cash Flow per Share Growth Rate was 78.30% per year. The lowest was -142.00% per year. And the median was 27.60% per year.

ARCT's 3-Year OCF Growth Rate is ranked better than
79.94% of 1241 companies
in the Biotechnology industry
Industry Median: 3.7 vs ARCT: 31.50

Arcturus Therapeutics Holdings Operating Cash Flow per Share Historical Data

The historical data trend for Arcturus Therapeutics Holdings's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings Operating Cash Flow per Share Chart

Arcturus Therapeutics Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.53

-2.11

-5.13

1.18

-0.68

Arcturus Therapeutics Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															5.51	-1.32	1.91	-1.22	-0.02

Competitive Comparison of Arcturus Therapeutics Holdings's Operating Cash Flow per Share

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcturus Therapeutics Holdings's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's Price-to-Operating-Cash-Flow falls into.

Arcturus Therapeutics Holdings Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Arcturus Therapeutics Holdings's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-18.099	/	26.628
	=	-0.68

Arcturus Therapeutics Holdings's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-0.629	/	26.835
	=	-0.02

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.65

Arcturus Therapeutics Holdings Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121

Website

https://www.arcturusrx.com

Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.

Executives

Pad Chivukula	officer: Chief Scientific Officer & COO	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith C Kummerfeld	officer: See Remarks	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels	director	C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne	director, 10 percent owner, officer: President and CEO	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc.	director, 10 percent owner	60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata	officer: Chief Legal Officer	10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Andy Sassine	officer: Chief Financial Officer	82 DEVONSHIRE STREET, BOSTON MA 02109
Steven George Hughes	officer: Chief Development Officer	6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow	director	2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes	director	C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell	director	RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer	director	60 LEVERONI COURT, NOVATO CA 94949